Forma Therapeutics Holdings, Inc. (FMTX)
| Market Cap | 1.22B |
| Revenue (ttm) | 7.44M |
| Net Income (ttm) | -121.34M |
| Shares Out | 47.37M |
| EPS (ttm) | -3.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $24.22 |
| Previous Close | $24.84 |
| Change ($) | -0.62 |
| Change (%) | -2.50% |
| Day's Open | 24.78 |
| Day's Range | 23.75 - 25.20 |
| Day's Volume | 217,463 |
| 52-Week Range | 21.10 - 56.33 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease. Data were presented at the Annual European Hematology Ass...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced new data ...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator. The 600 mg high-dose cohort featu...
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results from Q4 and full year 2020, as well as business updates.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive data from the 600 mg cohort in the Phase 1 trial of FT-4202 in sickle cell patients.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that the company will release fourth quarter and year-end 2020 financial results on Tuesday, March 30, 2021.
Forma Therapeutics (FMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces participation in three upcoming investor conferences.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the first patient dosed in Phase 1 clinical trial evaluating FT-7051 in metastatic castration-resistant prostate cancer.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics provides a review of 2020 company highlights and an outline of anticipated 2021 milestones.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that renowned doctor Selwyn M. Vickers, M.D., has been elected to the company's board of directors.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the closing of an underwritten public offering of 6,095,000 shares of its common stock.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the pricing of an underwritten public offering of 5,300,000 shares of its common stock.
WATERTOWN, MA--(BUSINESS WIRE)--Forma Therapeutics launches a proposed public offering of 4,600,000 shares of its common stock.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics presents clinical proof-of-concept data on FT-4202 in sickle cell disease at the 62nd ASH annual meeting.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces financial results for the third quarter ended September 30, 2020.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces EU Orphan Drug designation for FT-4202 for the treatment of sickle cell disease.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma announced that four abstracts have been accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma today announced that company management will participate in three upcoming investor conferences.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive top-line data from planned interim analysis of Phase 2 trial evaluating olutasidenib in acute myeloid leukemia.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointments of two new vice presidents
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the appointment of Thomas G.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results for the second quarter ended June 30, 2020 and provides business update.
WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces that Wayne A.I.
Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.
Investors fed their voracious appetites for biotech Friday when two life science companies traded well above offering prices in their market debuts.
About FMTX
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 ... [Read more...]
| Industry Biotechnology | IPO Date Jun 19, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol FMTX |
Analyst Forecasts
According to 5 analysts, the average rating for FMTX stock is "Strong Buy." The 12-month stock price forecast is 56.50, which is an increase of 133.28% from the latest price.